Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-Cell Depleted HSCT with TBI, Thiotepa, and Fludarabine
NCT00587054Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2001
- Primary completion
- May 2011
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thiotepa and fludarabine in acute leukemia, B-cell chronic lymphocytic leukemia (B-CLL), non-Hodgkin lymphoma (NHL) and 3 more, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Overall Survival at 6 years. Started Jun 2001; status: completed.
02
Drugs
thiotepafludarabine
03
Conditions
acute leukemiaB-cell chronic lymphocytic leukemia (B-CLL)non-Hodgkin lymphoma (NHL)lymphoblastic lymphoma (LL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00587054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00587054.